#United States #New York #Pomerantz LLP #SEC Investigation #Capricor Therapeutics

Pomerantz Law Firm Investigates Capricor Therapeutics

Pomerantz LLP has recently announced an investigation on behalf of investors of Capricor Therapeutics, Inc., a biopharmaceutical company known for its work in cell therapies. This probe is particularly significant as it aims to determine whether Capricor, along with some of its executives and directors, may have engaged in practices that constitute securities fraud or other unlawful business activities.

This investigation stems from a series of events surrounding Capricor's Biologics License Application (BLA) for deramiocel, an investigational cell therapy aimed at treating cardiomyopathy related to Duchenne muscular dystrophy (DMD). On May 5, 2025, Capricor released a statement after a mid-cycle review meeting with the FDA, confirming the agency's intention to convene an advisory committee meeting regarding their BLA submission. Following this announcement, the company's stock price took a 29.13% hit, dropping by $3.00 to close at $7.30 on May 6, 2025.

The story took another turn on June 20, 2025, when the publication STAT reported that the recently appointed head of the relevant FDA unit had decided to cancel the advisory committee meeting. This cancellation was attributed to uncertainty surrounding the drug's efficacy and safety, which led to a further decline in Capricor's stock price by $3.68, or 30.82%, closing at $8.26 per share.

Pomerantz LLP, with a rich history of over 85 years, is recognized as one of the leading law firms specializing in corporate, securities, and antitrust class litigation. The firm, founded by the late Abraham L. Pomerantz, has a long-standing reputation for advocating on behalf of victims affected by securities fraud and corporate misconduct. The firm has a successful track record of securing substantial damage awards for those affected by such actions.

The current investigation invites investors with relevant information or those who have been impacted to come forward and connect with Danielle Peyton at Pomerantz LLP.

As this situation develops, investors remain watchful, hoping for clarity and justice for those who may have suffered losses due to alleged misinformation or mismanagement by Capricor and its leadership. The outcome of these investigations may not just impact the company but could also influence the wider market perception of burgeoning biotech firms navigating the complexities of drug approvals.

Conclusion

Pomerantz LLP’s investigation into Capricor Therapeutics acts as a critical reminder of the complex and sometimes risky nature of investing in pharmaceutical companies, particularly those working with high-stakes, investigational therapies. Investors should stay informed of the developments arising from this case as they could have lasting implications for Capricor and its future operations.